keyword
MENU ▼
Read by QxMD icon Read
search

Colorectal cancer liver metastases

keyword
https://www.readbyqxmd.com/read/29790787/colorectal-liver-metastases-a-pathologist-s-guide-to-creating-an-informative-report-and-improving-patient-care
#1
Mariana Moreno Prats, Eizaburo Sasatomi, Heather L Stevenson
CONTEXT: - In this era of minimally invasive procedures for diagnosis, prognosis, and treatment, pathologists are at the forefront of analyzing specimens and are expected to make more specific diagnoses, providing additional information from the material they receive. OBJECTIVE: - To familiarize pathologists with the essential components of surgical pathology reports for colorectal liver metastases (CRLM) resections. DATA SOURCES: - Colorectal cancer is the third most common cancer in the world and the liver is the most frequent site of metastases...
May 23, 2018: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/29786130/ras-mutation-is-associated-with-unsalvageable-recurrence-following-hepatectomy-for-colorectal-cancer-liver-metastases
#2
Masayuki Okuno, Claire Goumard, Scott Kopetz, Eduardo A Vega, Katharina Joechle, Takashi Mizuno, Kiyohiko Omichi, Ching-Wei D Tzeng, Yun Shin Chun, Jean-Nicolas Vauthey, Claudius Conrad
BACKGROUND: RAS mutation status predicts survival after hepatectomy for colorectal liver metastases (CRLM) and survival after repeat hepatectomy for intrahepatic recurrence. This study was aimed at determining the impact of RAS mutation on amenability of recurrence to local therapy and on post-recurrence survival following hepatectomy. METHODS: CRLM patients with recurrence at any location after curative intent hepatectomy during the period 2006-2015 were retrospectively analyzed...
May 21, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29783886/the-impact-of-surgical-resection-of-the-primary-tumor-on-the-development-of-synchronous-colorectal-liver-metastasis-a-systematic-review
#3
H Pinson, S Cosyns, Wim P Ceelen
BACKGROUND: In recent years different therapeutic strategies for synchronously liver metastasized colorectal cancer were described. Apart from the classical staged surgical approach, simultaneous and liver-first strategies are now commonly used. One theoretical drawback of the classical approach is, however, the stimulatory effect on liver metastases growth that may result from resection of the primary tumour. This systematic review, therefore, aims to investigate the current insights on the stimulatory effects of colorectal surgery on the growth of synchronous colorectal liver metastases in humans...
May 22, 2018: Acta Chirurgica Belgica
https://www.readbyqxmd.com/read/29766239/-90-y-resin-microspheres-radioembolization-for-colon-cancer-liver-metastases-using-full-strength-contrast-material
#4
I Kurilova, R G H Beets-Tan, G A Ulaner, F E Boas, E N Petre, H Yarmohammadi, E Ziv, A R Deipolyi, L A Brody, M Gonen, Constantinos T Sofocleous
OBJECTIVES: To assess safety and efficacy of 90 Y resin microspheres administration using undiluted non-ionic contrast material (UDCM) {100% Omnipaque-300 (Iohexol)} in both the "B" and "D" lines. MATERIALS AND METHODS: We reviewed all colorectal cancer liver metastases patients treated with 90 Y resin microspheres radioembolization (RAE) from 2009 to 2017. As of April 2013, two experienced operators started using UDCM (study group) instead of standard sandwich infusion (control group)...
May 15, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29762149/pseudoadjuvant-chemotherapy-in-resectable-metastatic-colorectal-cancer
#5
Laura Polastro, Georges El Hachem, Alain Hendlisz
PURPOSE OF REVIEW: In this article, we focus on the potential benefits and risks of chemotherapy administration before (perioperative) or after (pseudoadjuvant) a curative resection of colorectal cancer (CRC) metastases. RECENT FINDINGS: In the published evidence, there is a lack of survival benefit from peri or postoperative chemotherapy in the context of resectable metastatic CRC. However, high-risk patients may have a certain benefit when receiving a postoperative cytotoxic treatment...
May 11, 2018: Current Opinion in Oncology
https://www.readbyqxmd.com/read/29760793/hepatitis-b-virus-infection-predicts-better-survival-in-patients-with-colorectal-liver-only-metastases-undergoing-liver-resection
#6
Yujie Zhao, Junzhong Lin, Jianhong Peng, Yuxiang Deng, Ruixia Zhao, Qiaoqi Sui, Zhenhai Lu, Desen Wan, Zhizhong Pan
Objective: Hepatitis B virus (HBV) infection has been shown to decrease the risk of liver metastasis in patients with non-metastatic colorectal cancer (CRC). However, the prognostic value of HBV infection in long-term survival of patients with colorectal liver-only metastases (CRLM) after liver resection has not yet been evaluated. This study aims to explore the association between HBV infection and survival in CRLM patients. Methods: A total of 289 CRLM patients undergoing liver resection were recruited at our center from September 1999 to August 2015...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29756328/serum-derived-carcinoembryonic-antigen-cea-activates-fibroblasts-to-induce-a-local-re-modeling-of-the-extracellular-matrix-that-favors-the-engraftment-of-cea-expressing-tumor-cells
#7
Aws Abdul-Wahid, Marzena Cydzik, Nicholas W Fischer, Aaron Prodeus, John E Shively, Anne Martel, Samira Alminawi, Zeina Ghorab, Neil L Berinstein, Jean Gariépy
Elevated levels of the carcinoembryonic antigen (CEA; CEACAM5) in the serum of colorectal cancer (CRC) patients represent a clinical biomarker that correlates with disease recurrence. However, a mechanistic role for soluble CEA (sCEA) in tumor progression and metastasis remains to be established. In this study, we report that sCEA acts as a paracrine factor, activating human fibroblasts by signalling through both the STAT3 and AKT1-mTORC1 pathways, promoting their transition to a cancer-associated fibroblast (CaF) phenotype...
May 14, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29755783/erratum-to-updated-survival-outcomes-and-analysis-of-long-term-survivors-from-the-more-study-on-safety-and-efficacy-of-radioembolization-in-patients-with-unresectable-colorectal-cancer-liver-metastases
#8
Andrew Kennedy, Michael Cohn, Douglas M Coldwell, Alain Drooz, Eduardo Ehrenwald, Adeel Kaiser, Charles W Nutting, Steven C Rose, Eric A Wang, Michael A Savin
[This corrects the article DOI: 10.21037/jgo.2017.03.10.].
April 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29754852/predictors-of-survival-after-yttrium-90-radioembolization-for-colorectal-cancer-liver-metastases
#9
Ashley A Weiner, Bin Gui, Neil B Newman, John L Nosher, Fady Yousseff, Shou-En Lu, Gretchen M Foltz, Darren Carpizo, Jonathan Lowenthal, Darryl A Zuckerman, Ben Benson, Jeffrey R Olsen, Salma K Jabbour, Parag J Parikh
PURPOSE: To identify clinical parameters that are prognostic for improved overall survival (OS) after yttrium-90 radioembolization (RE) in patients with liver metastases from colorectal cancer (CRC). MATERIALS AND METHODS: A total of 131 patients who underwent RE for liver metastases from CRC, treated at 2 academic centers, were reviewed. Twenty-one baseline pretreatment clinical factors were analyzed in relation to OS by the Kaplan-Meier method along with log-rank tests and univariate and multivariate Cox regression analyses...
May 10, 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29752549/promising-new-agents-for-colorectal-cancer
#10
REVIEW
Satya Das, Kristen K Ciombor, Sigurdis Haraldsdottir, Richard M Goldberg
Choosing the optimal treatment approach for patients with metastatic colorectal cancer (mCRC) demands that oncologists assess both clinical and genomic variables and individualize care based upon the findings. Clinically, choices depend on assessing the side of the colon in which the primary tumor originates, the sites and burden of metastatic disease, the patient's performance status, and their individual comorbidities. Genomic assessment of the tumor to discern the mutational status of genes such as RAS/RAF, HER2, and TRK, as well as assessing whether tumors have defective mismatch repair (dMMR) or high microsatellite instability (MSI-H), all factor in to potential treatment options and can determine clinical trial eligibility...
May 11, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29746284/the-concept-of-oligometastases-in-colorectal-cancer-from-the-clinical-evidences-to-new-therapeutic-strategies
#11
Edouard Massaut, Ali Bohlok, Valerio Lucidi, Alain Hendlisz, Jean Klastersky, Vincent Donckier
PURPOSE OF REVIEW: The concept of oligometastases, defining cancers with limited metastatic capacity and attaining a limited number of secondary sites, is now widely accepted, particularly in colorectal cancer. Currently, however, accurate predictive markers for oligometastatic tumors are still lacking. For this reason, it remains challenging to translate this concept into clinical recommendations. In the present work, we review recent publications on oligometastases in colorectal cancer, showing the evidences for such presentation and underlying the need for the identification of biomarkers, necessary to further develop new therapeutic strategies...
May 4, 2018: Current Opinion in Oncology
https://www.readbyqxmd.com/read/29745068/topics-related-to-neoadjuvant-chemotherapy-for-resectable-liver-metastases-from-colorectal-cancer
#12
Shanbao Ke, Shufang Zhan, Hongbo Zhu, Danfang Yan
Metastases to the liver from colorectal cancer (CRC) are common, and only a minority of patients are candidates for upfront surgery at the initial diagnosis. Carefully selected patients can achieve long-term survival from surgery with curative intent. Unfortunately, the risk of recurrence remains substantial after liver resection. In order to reduce the risk of relapse and improve the outcomes, the role of neoadjuvant chemotherapy has been assessed for resectable colorectal liver metastases (CRLM) with an improvement in progression-free survival (PFS)...
March 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29744348/treatment-plan-improvement-by-multidisciplinary-case-conferences-for-patients-with-colorectal-cancer-and-synchronous-liver-metastases
#13
EDITORIAL
Markus Rentsch, Tobias S Schiergens
No abstract text is available yet for this article.
April 2018: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/29743154/oncosurgical-management-of-liver-limited-stage-iv-colorectal-cancer-preliminary-data-and-protocol-for-a-randomized-controlled-trial
#14
Paul Sutton, Dale Vimalachandran, Graeme Poston, Stephen Fenwick, Hassan Malik
BACKGROUND: Colorectal cancer is the fourth commonest cancer and second commonest cause of cancer-related death in the United Kingdom. Almost 15% of patients have metastases on presentation. An increasing number of surgical strategies and better neoadjuvant treatment options are responsible for more patients undergoing resection of liver metastases, with prolonged survival in a select group of patients who present with synchronous disease. It is clear that the optimal strategy for the management of these patients remains unclear, and there is certainly a complete absence of Level 1 evidence in the literature...
May 9, 2018: JMIR Research Protocols
https://www.readbyqxmd.com/read/29737864/panitumumab-in-the-treatment-of-metastatic-colorectal-cancer-including-wild-type-ras-kras-and-nras-mcrc
#15
Mark McGregor, Timothy J Price
The humanized monoclonal antibody panitumumab, targeted against EGFR, plays an important role in patients with metastatic colorectal cancer. This article reviews the body of evidence for panitumumab which demonstrates significant benefits across multiple lines of therapy in those without an extended RAS mutation. The use of panitumumab with RAS mutations is not beneficial and possibly harmful. Panitumumab is well tolerated with manageable toxicities. The role of panitumumab continues to evolve as understanding of sequencing of therapies grows...
May 8, 2018: Future Oncology
https://www.readbyqxmd.com/read/29736851/towards-volumetric-thresholds-in-recist-1-1-therapeutic-response-assessment-in-hepatic-metastases
#16
Katharina S Winter, Felix O Hofmann, Kolja M Thierfelder, Julian W Holch, Nina Hesse, Alena B Baumann, Dominik P Modest, Sebastian Stintzing, Volker Heinemann, Jens Ricke, Wieland H Sommer, Melvin D'Anastasi
OBJECTIVES: To empirically determine thresholds for volumetric assessment of response and progress of liver metastases in line with the unidimensional RECIST thresholds. METHODS: Patients with metastatic colorectal cancer initially enrolled in a multicentre clinical phase-III trial were included. In all CT scans, the longest axial diameters and volumes of hepatic lesions were determined semi-automatically. The sum of diameters and volumes of 1, ≤2 and ≤5 metastases were compared to all previous examinations...
May 7, 2018: European Radiology
https://www.readbyqxmd.com/read/29736846/diagnostic-accuracy-of-ce-ct-mri-and-fdg-pet-ct-for-detecting-colorectal-cancer-liver-metastases-in-patients-considered-eligible-for-hepatic-resection-and-or-local-ablation
#17
Kim Sivesgaard, Lars P Larsen, Michael Sørensen, Stine Kramer, Sven Schlander, Nerijus Amanavicius, Arindam Bharadwaz, Dennis Tønner Nielsen, Frank Viborg Mortensen, Erik Morre Pedersen
PURPOSE: To compare the diagnostic performance of contrast-enhanced computed tomography (CE-CT), magnetic resonance imaging (MRI) and combined fluorodeoxyglucose/positron emission tomography/computed tomography (FDG-PET/CT) for detection of colorectal liver metastases (CRLM) in patients eligible for local treatment. MATERIALS AND METHODS: This health-research ethics-committee-approved prospective consecutive diagnostic accuracy study, with written informed consent, included 80 cases (76 patients, four participating twice) between 29 June 2015 and 7 February 2017...
May 7, 2018: European Radiology
https://www.readbyqxmd.com/read/29731961/macrophages-induce-budding-in-aggressive-human-colon-cancer-subtypes-by-protease-mediated-disruption-of-tight-junctions
#18
Kari Trumpi, Nicola Frenkel, Timo Peters, Nicoline M Korthagen, Jennifer M J Jongen, Daniëlle Raats, Helma van Grevenstein, Yara Backes, Leon M Moons, Miangela M Lacle, Jan Koster, Danny Zwijnenburg, Inne H M Borel Rinkes, Onno Kranenburg
Primary human colorectal tumors with a high stromal content have an increased capacity to metastasize. Cancer-associated fibroblasts (CAFs) promote metastasis, but the contribution of other stromal cell types is unclear. Here we searched for additional stromal cell types that contribute to aggressive tumor cell behavior. By making use of the 'immunome compendium'-a collection of gene signatures reflecting the presence of specific immune cell-types-we show that macrophage signatures are most strongly associated with a high CAF content and with poor prognosis in multiple large cohorts of primary tumors and liver metastases...
April 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29731866/microrna-hsa-let-7e-5p-as-a-potential-prognosis-marker-for-rectal-carcinoma-with-liver-metastases
#19
Wenfeng Chen, Guosheng Lin, Yizhou Yao, Jishen Chen, Hanli Shui, Qinghai Yang, Xiaoya Wang, Xiaoyuan Weng, Ling Sun, Fei Chen, Sheng Yang, Yufeng Yang, Yongjian Zhou
MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression that target mRNAs for translational repression or cleavage. The present study was conducted to identify differentially expressed miRNAs in primary tumor tissues of rectal carcinoma (RC) that may be associated with heterochrony hepatic metastasis (HHM). Samples were collected exclusively from patients with RC but not colon cancer (CC); Next-generation high-throughput sequencing technology and bioinformatics tools were used to profile and analyze small RNAs and their corresponding targets in primary tumor tissues with HHM (n=2) or without metastases (non-metastatic, NM; n=2)...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29728604/integrated-molecular-subtyping-defines-a-curable-oligometastatic-state-in-colorectal-liver-metastasis
#20
Sean P Pitroda, Nikolai N Khodarev, Lei Huang, Abhineet Uppal, Sean C Wightman, Sabha Ganai, Nora Joseph, Jason Pitt, Miguel Brown, Martin Forde, Kathy Mangold, Lai Xue, Christopher Weber, Jeremy P Segal, Sabah Kadri, Melinda E Stack, Sajid Khan, Philip Paty, Karen Kaul, Jorge Andrade, Kevin P White, Mark Talamonti, Mitchell C Posner, Samuel Hellman, Ralph R Weichselbaum
The oligometastasis hypothesis suggests a spectrum of metastatic virulence where some metastases are limited in extent and curable with focal therapies. A subset of patients with metastatic colorectal cancer achieves prolonged survival after resection of liver metastases consistent with oligometastasis. Here we define three robust subtypes of de novo colorectal liver metastasis through integrative molecular analysis. Patients with metastases exhibiting MSI-independent immune activation experience the most favorable survival...
May 4, 2018: Nature Communications
keyword
keyword
48140
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"